EMEA-001517-PIP02-14-M02

Key facts

Active substance
Sotagliflozin
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0337/2017
PIP number
EMEA-001517-PIP02-14-M02
Pharmaceutical form(s)
  • Granules
  • Tablets
Condition(s) / indication(s)
Treatment of type I diabetes mellitus
Route(s) of administration
Oral use
Contact for public enquiries
Navigant Germany GmbH

Tel: +19089638536
E-mail: KKasslerTaub@lexpharma.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating